QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
Top-Rated StocksTop-Rated
NASDAQ:IPSC

Century Therapeutics (IPSC) Stock Forecast, Price & News

$3.38
+0.18 (+5.63%)
(As of 06/7/2023 ET)
Compare
Today's Range
$3.19
▼
$3.43
50-Day Range
$2.91
▼
$3.53
52-Week Range
$2.81
▼
$14.00
Volume
127,674 shs
Average Volume
160,172 shs
Market Capitalization
$201.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Century Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
462.1% Upside
$19.00 Price Target
Short Interest
Bearish
6.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$295,202 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.07) to ($1.95) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.65 out of 5 stars

Medical Sector

827th out of 981 stocks

Biological Products, Except Diagnostic Industry

128th out of 159 stocks

See Top Rated MarketRank™ Stocks Here

IPSC stock logo

About Century Therapeutics (NASDAQ:IPSC) Stock

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Receive IPSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

IPSC Stock News Headlines

May 26, 2023 | americanbankingnews.com
Brokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) Target Price at $19.00
May 12, 2023 | markets.businessinsider.com
H.C. Wainwright Keeps Their Buy Rating on Century Therapeutics (IPSC)
June 7, 2023 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
May 12, 2023 | finance.yahoo.com
Century Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags
May 11, 2023 | msn.com
Century Therapeutics: Q1 Earnings Insights
May 11, 2023 | finanznachrichten.de
Century Therapeutics, Inc.: Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
May 11, 2023 | finance.yahoo.com
Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Lags Revenue Estimates
May 11, 2023 | finance.yahoo.com
Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
June 7, 2023 | Altimetry (Ad)
Biden's latest bailout--terrible for America?
And a consultant for the Dept. of Defense (Joel Litman) says this is all leading to an event in the next 20 months that could help some get vastly wealthier… but also make it harder than ever to hang onto any money you make.This might be the most important development affecting you and your money over the next few years—
May 1, 2023 | americanbankingnews.com
Analysts Set Century Therapeutics, Inc. (NASDAQ:IPSC) PT at $19.00
April 19, 2023 | americanbankingnews.com
EF Hutton Acquisition Co. I Reiterates "Buy" Rating for Century Therapeutics (NASDAQ:IPSC)
April 17, 2023 | benzinga.com
Century Therapeutics to Present at Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit
April 13, 2023 | msn.com
HC Wainwright & Co. Reiterates Century Therapeutics (IPSC) Buy Recommendation
April 13, 2023 | markets.businessinsider.com
Analyst Ratings for Century Therapeutics
April 13, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY) and Century Therapeutics (IPSC)
April 12, 2023 | msn.com
Century Therapeutics CEO Lalo Flores steps down, Greg Russotti appointed as ad-interim Chief Executive Officer
April 12, 2023 | bizjournals.com
Century Therapeutics CEO departs amid shakeup in C-suite
April 12, 2023 | finance.yahoo.com
Century Therapeutics Announces Leadership Changes
March 29, 2023 | americanbankingnews.com
FY2023 EPS Estimates for Century Therapeutics, Inc. (NASDAQ:IPSC) Boosted by Chardan Capital
March 25, 2023 | americanbankingnews.com
Century Therapeutics, Inc. (NASDAQ:IPSC) Insider Luis Borges Sells 15,597 Shares
March 22, 2023 | americanbankingnews.com
Chardan Capital Reaffirms "Buy" Rating for Century Therapeutics (NASDAQ:IPSC)
March 22, 2023 | americanbankingnews.com
Research Analysts Offer Predictions for Century Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:IPSC)
March 22, 2023 | americanbankingnews.com
Century Therapeutics, Inc. (NASDAQ:IPSC) Forecasted to Post Q1 2024 Earnings of ($0.48) Per Share
March 21, 2023 | markets.businessinsider.com
Chardan Capital Sticks to Their Buy Rating for Century Therapeutics (IPSC)
March 21, 2023 | americanbankingnews.com
Bank of America Cuts Century Therapeutics (NASDAQ:IPSC) Price Target to $20.00
March 20, 2023 | msn.com
Century Therapeutics's Return On Capital Employed Overview
March 16, 2023 | markets.businessinsider.com
EF Hutton Sticks to Their Buy Rating for Century Therapeutics (IPSC)
See More Headlines

IPSC Price History

IPSC Company Calendar

Last Earnings
3/16/2023
Today
6/07/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IPSC
CUSIP
N/A
CIK
1850119
Web
www.centurytx.com
Phone
267-817-5790
Fax
N/A
Employees
170
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.00
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+462.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.15)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-130,930,000.00
Net Margins
-2,127.33%
Pretax Margin
-2,105.44%
Return on Equity
-39.33%
Return on Assets
-25.10%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.24
Quick Ratio
9.24

Sales & Book Value

Annual Sales
$5.20 million
Price / Sales
38.73
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.13 per share
Price / Book
0.66

Miscellaneous

Outstanding Shares
59,580,000
Free Float
55,053,000
Market Cap
$201.38 million
Optionable
Not Optionable
Beta
0.59

Key Executives

  • Dr. Osvaldo Flores Ph.D.Dr. Osvaldo Flores Ph.D. (Age 59)
    Pres, CEO & Director
    Comp: $778.06k
  • Dr. Adrienne Farid Ph.D. (Age 60)
    Chief Operations Officer
    Comp: $589.47k
  • Dr. Luis Borges (Age 60)
    Chief Scientific Officer
    Comp: $604.12k
  • Mr. Douglas Carr CPA
    VP of Fin. and Operations & Sec.
  • Dr. Gregory Russotti Ph.D. (Age 55)
    Chief Technology Officer
  • Mr. Kenneth J. Dow J.D.
    Head of Legal & Compliance
  • Dr. Shane Williams Ph.D.
    Chief People Officer
  • Dr. Michael C. Diem (Age 51)
    Chief Bus. Officer
  • Dr. Hyam I. Levitsky M.D. (Age 64)
    Pres of R&D
  • Mr. Mark Wallet
    Head of Immunology & VP

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













IPSC Stock - Frequently Asked Questions

Should I buy or sell Century Therapeutics stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Century Therapeutics in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IPSC shares.
View IPSC analyst ratings or view top-rated stocks.

What is Century Therapeutics' stock price forecast for 2023?

9 equities research analysts have issued 12 month price objectives for Century Therapeutics' shares. Their IPSC share price forecasts range from $14.00 to $28.00. On average, they predict the company's share price to reach $19.00 in the next year. This suggests a possible upside of 462.1% from the stock's current price.
View analysts price targets for IPSC or view top-rated stocks among Wall Street analysts.

How have IPSC shares performed in 2023?

Century Therapeutics' stock was trading at $5.13 on January 1st, 2023. Since then, IPSC stock has decreased by 34.1% and is now trading at $3.38.
View the best growth stocks for 2023 here.

When is Century Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our IPSC earnings forecast.

How were Century Therapeutics' earnings last quarter?

Century Therapeutics, Inc. (NASDAQ:IPSC) posted its quarterly earnings data on Thursday, March, 16th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.05. The company had revenue of $0.52 million for the quarter, compared to analyst estimates of $2.80 million. Century Therapeutics had a negative net margin of 2,127.33% and a negative trailing twelve-month return on equity of 39.33%.

When did Century Therapeutics IPO?

(IPSC) raised $201 million in an IPO on Friday, June 18th 2021. The company issued 10,600,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

What is Century Therapeutics' stock symbol?

Century Therapeutics trades on the NASDAQ under the ticker symbol "IPSC."

Who are Century Therapeutics' major shareholders?

Century Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (8.97%), BlackRock Inc. (2.37%), Geode Capital Management LLC (0.71%), State Street Corp (0.62%), Renaissance Technologies LLC (0.26%) and New York Life Investment Management LLC (0.22%). Insiders that own company stock include Eli Casdin, Luis Borges and Versant Venture Capital Vi, L.
View institutional ownership trends.

How do I buy shares of Century Therapeutics?

Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Century Therapeutics' stock price today?

One share of IPSC stock can currently be purchased for approximately $3.38.

How much money does Century Therapeutics make?

Century Therapeutics (NASDAQ:IPSC) has a market capitalization of $201.38 million and generates $5.20 million in revenue each year. The company earns $-130,930,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis.

How many employees does Century Therapeutics have?

The company employs 170 workers across the globe.

How can I contact Century Therapeutics?

The official website for the company is www.centurytx.com. The company can be reached via phone at 267-817-5790 or via email at investor.relations@centurytx.com.

This page (NASDAQ:IPSC) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -